Member Info for Dibs61

Agreed, a very positive statement and, like many, I’m largely interested in Bushranger as I have my doubts the various other African interests are ever going to produce anything meaningful - just my jaundiced view mind.

So here’s the Bushranger bit:

“A major step for the Company was the acquisition of the Bushranger Copper-Gold project in NSW, Australia in late October 2020 and we commenced drilling on 16 December 2020. We drilled 5 holes, all of which encountered considerable widths of copper mineralisation, with the first hole encountering 920m of continuous mineralisation. Post balance sheet, we completed the programme, received some assay results, conducted a major geophysical programme and did some initial open pit modelling.

The results of the geophysics have been extremely encouraging and the porphyry appears to be open in all directions, with particularly strong indications of mineralisation to the northwest and southeast at relatively shallow depths. The Directors were extremely encouraged by the results of the initial programme and are planning a second drilling programme to commence early Quarter 3, 2021 for at least 20,000m. We are currently modelling a potential open pit, based on previous drill holes and eagerly await the outcome of the modelling against more positive copper prices and mid-term projections.

The Racecourse Project in the Lachlan Fold Belt has well surpassed our expectations and we look forward with anticipation to phase 2 of the drilling programme.”

So do I Colin, so do I…..!

Does the market still have faith in the project here. Looking back over the last year or so, we hit a max closing high of 250p and at that time, with less shares in issue (pre-placing) we were valued at £375m. At the current price of 171p we are valued at £342m. So I think we can still say the market firmly believes in the story here. Indeed when we recently hit an intraday day high of 190p that represented an all time high market valuation. Not a bad performance against a backdrop of seemingly unfavourable media ie.vaccine cures all, SNG gets little or no coverage in UK etc

Taking all this into account the SP performance has been fairly impressive.

BOJO I guess in that case it’s better having a half wit than no wit :)

This is painful but would be a ridiculous decision to exit at this price.

Very unhappy with Mr Bird for the worrying inconsistency of his communications strategy. Goes from one extreme to another. Hasn’t delivered what he said would be delivered vis a vis the assay results re timeframes etc

It does seem though that the price is dropping on consistently low volume and no concerning holdings RNS’s have dropped.

Hoping for a much more positive H2! Can’t be much worse can it?

“Pressed on the question of whether allowing travel from India caused the UK's third wave of infections, Hopkins says: "We recognise now if you’ve got an epidemic in another country that will increase cases in this country."

But she says the UK is learning to live with the virus as it lives with respiratory viruses every winter. That is likely to mean booster vaccinations for the vulnerable and drug treatments for those who get infected.

Hopkins says she expects to see new drugs to treat people early and prevent them from being admitted to hospital.

She says lockdowns aren't likely to be a part of living with coronavirus. "We wouldn't normally put people into lockdown for flu", she says.

Hopkins adds that we "may have to do further lockdowns this winter", depending on hospital admissions, but we will also have alternatives.

OK then she specifically mentions future policy to include the use of drug treatments for Covid 19 and this comment in particular is interesting:

“expects to see new drugs to treat people early and prevent them from being admitted to hospital”.

If there was just a treatment that was effective against ANY variant, any mutation ….. unlike MAB’s…. Oh hang on it’s right under their noses

Xvoilet - it’s no rumour. He said it.

If you’ve got the cash to spare to buy or top up this mornings drop is an absolute gift horse.

The point is the ‘correction’ itself is incorrect. He did not say it had ‘moved’ he said it was ‘moving’ to P3.

‘Moved’ and ‘Moving’ are two separate things. One is the past tense the other is the current tense.

The ‘correction’ against his words is incorrect itself! IIRC he said it’s ‘moving’ to P3 not that it has ‘moved’. That’s important. Yes it’s no doubt still in P2 technically but the point is he did tell the truth - it’s ‘moving’ to P3!

https://investegate.co.uk/cap-xx-limited--cpx-/rns/sensys-networks-selects-cap-xx-supercapacitors/202106160700069738B/

Yes, further endorsement of CPX supercapacitor product.

Yes this is getting unnecessarily confusing. Either they are moving to P3 or they’re not. It’s not the company’s fault but clarification is now required.

I simply cannot believe the guy who is actually leading the overall programme could’ve made such a huge and basic mistake? Does he really not understand what is happening with one of just a small number of drugs in the trial? If he has gaffed and it was a mistake, I mean that to me would be extraordinary.

Woodstock - now I’m offended that you’ve excluded me from your closing SNG LSE Obituary!

Ha! He has realised he boobed. It was no mistake for sure. It’s just he failed to follow the protocol and had to backtrack. But by saying it’s still in P2, well of course it could be but it’s clearly going to P3! Maybe that’s why the market hesitated after the initial spike due to the confusion?

Whatever, onwards and upwards

Not sure. My gut feeling is the company may not have been planning to yet. I wonder of RM and SNG management may be a little irked by this (big) information getting out before they have officially announced to the market?

If not tomorrow then you would’ve thought RNS by the end of the week.

No question though it’s a big development and a further endorsement of the drugs capability from an entirely new and different source adding further gravitas.

Anyone else glad they stuck around….;)

Last reported revenue for interim 30 Sept last year - £3.16m

Current market valuation £116m

This is either vastly overvalued or there is already a LOT of sales already baked into the price at 63p

Be careful

I had no idea there was such a thing as Level 3 trading? Is that an official term or just a kind of loose expression of dark pool trading that you’re referring to?

In any case it does appear that supply is tightening which, let’s face it, at this depressed SP level one might expect!

You get contracts from customers for the supply of products NOT for providing a certain capacity for the theoretical potential future sale of products. Terms like’contracts’ have been used spuriously here. A true ‘contract’ with a customer would provide revenue for the supply of product.

We are now some 16/17 months into the pandemic.

So, I ask again, how many Antigen LFT’s have ODX sold?

Come to think of it how many of the once fabled Rapid ABC tests have ODX sold?

And what is the market valuation here and the latest revenue figures?

Maybe that’s why it’s taking longer to sort out because they want to relist on main market - that’s a condition of the deal - rather than AIM? He said hopefully...